ICH Q9 Provides Implementation Framework For Quality Risk Management
This article was originally published in The Pink Sheet Daily
Executive Summary
ICH's quality risk management draft guideline "Q9" provides a common language and systematic approach that will facilitate industry/regulator communications. ICH Q9 is intended to provide a practical toolbox to accompany the pharmaceutical development ("Q8") and newly agreed to quality systems ("Q10") facets of the ICH effort to evolve a more harmonized and flexible quality oversight process.
You may also be interested in...
GMP “Design Space” To Facilitate FDA Quality Initiative Implementation
“Design Space” is emerging as a pivotal concept in FDA’s effort to integrate its pharmaceutical application review and inspection operations into a new “quality assessment” system. With regulatory flexibility for manufacturing changes in the balance, the agency will be working with industry to refine the concept and its application in drug development and manufacturing.
Guidances, Position Papers Help Set Quality Initiative’s Future Course
The two-year anniversary of FDA’s quality initiative marks a shift in focus from assessment and design to implementation. With the conceptual framework in place, FDA and industry are now turning their attention to putting principles into practice.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.